According to a recent LinkedIn post from Circular Genomics, the company is adding Henrik Zetterberg, M.D., Ph.D., to its Scientific Advisory Board. The post describes Zetterberg as a leading expert in fluid biomarkers for neurodegenerative diseases and notes his academic roles at the University of Gothenburg, University of Wisconsin–Madison, and University College London.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The post suggests that his involvement is intended to support Circular Genomics’ efforts to develop circRNA biomarker technology for brain disorders. It specifically references work on blood‑based assays aimed at Alzheimer’s disease diagnosis and risk prediction, indicating a focus on translating biomarker science into clinically applicable tools.
For investors, the appointment points to a continued emphasis on scientific credibility and potential clinical relevance in the neurodegenerative space. Bringing in a globally recognized biomarker specialist could strengthen the company’s research direction, partnership prospects, and long‑term positioning in diagnostic markets tied to Alzheimer’s and other brain disorders.
The focus on blood‑based assays may also align with broader industry trends toward less invasive, scalable diagnostic solutions. If Circular Genomics can leverage this advisory expertise into validated products, it could enhance the company’s competitive profile in precision neurology and support future funding or commercialization discussions.